Impairment of cardiac metabolism and sympathetic innervation after aneurysmal subarachnoid hemorrhage: a nuclear medicine imaging study

Table 2 Initial gravity, cardiac damage, neurological outcomes, and quality-of-life assessment according to normal/abnormal initial ¹⁸ F-FDG PET

	Initial normal PET (n = 5)	Initial abnormal PET (n = 25)	Initial normal PET vs. initial abnormal PET
Fisher grade (1/2/3/4), n (%)	0 (0%)/0 (0%)/	0 (0%)/3 (12%)/	-
Fisher grade (1/2/3/4), n (%)	1 (20%)/4 (80%)	8 (32%)/14 (56%)	-
WFNS (1/2/3/4/5), n (%)	1 (20%)/1 (20%)/	11 (44%)/5 (20%)	-
	2 (40%)/0 (0%)/	/1 (4%)/0 (0%)/
	1 (20%)	8 (32%)
Echocardiography (mean ± SD)
LVEF,%	64.2 ± 6.1	61.9 ± 4.6	NS
E/A	0.9 ± 0.3	1.1 ± 0.3	NS
E/Ea	6.1 ± 2.6	4.9 ± 2.4	NS
Cardiac biomarkers [Median interquartile range]
Troponin T peak, μg/l	0.03 [0-0.04]	0 [0-0.09]	NS
Neurological outcomes (mean ± SD)
mRS 1 month	4.5 ± 1.4	3.9 ± 1.4	NS
mRS 3 months	3.7 ± 1.8	3.2 ± 1.6	NS
mRS 6 months	3.3 ± 2.1	2.7 ± 1.8	NS
Quality of life (mean ± SD)
MCS 3 months	63 ± 6	46 ± 18	NS
MCS 6 months	54 ± 11	55 ± 17	NS
PCS 3 months	64 ± 7	44 ± 15	NS
PCS 6 months	57 ± 21	55 ± 19	NS

Troponin T values denote the peak daily dosage during the first seven days. Statistical significance was accepted at P <0.05. ¹⁸ F-FDG PET, ¹⁸ F-fluorodesoxyglucose positron emission tomography; LVEF, left ventricular ejection fraction; mRS, modified Rankin Scale; MCS, mental component summary scale; NS, non-significant; PCS, physical component summary scale; WFNS, World Federation of Neurosurgical Societies.

ISSN: 1364-8535